cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.24503980.v1
title: Supplementary Material for: CLEAR CELL CARCINOMA ARISING IN LOW-GRADE MULLERIAN ADENOSARCOMA: FIRST REPORTED CASE WITH INSIGHT INTO MOLECULAR PROFILE

description: Uterine adenosarcoma is a rare biphasic neoplasm composed of a malignant, usually low-grade stromal component and benign epithelial component, usually endometrioid. Pathogenesis is unknown; some cases are undoubtably associated with tamoxifen use. Endometrial clear cell carcinoma (CCC) is an aggressive subtype of endometrial cancer, accounting for less than 10% of all uterine carcinomas. The etiology is unknown but can rarely be associated with Lynch syndrome and tamoxifen administration. The development of a composite neoplasm consisting of adenocarcinoma in adenosarcoma is extremely rare. Endometrioid carcinoma typically represents the epithelial component of the composite tumor. Here we present the very first case of composite tumor, namely adenosarcoma with clear cell carcinoma in which next-generation sequencing was performed. Patient was an 85-years-old woman treated with tamoxifen for five years. To better understand the pathobiology of two tumors, a targeted genomic analysis of both components was performed. We found seven identical somatic variants in the samples of both tumors, indicating that the tumors have a high probability of having the same origin. Dual amplification of CDK4 and MDM2 was the most likely primary cause of tumor formation, but also one driver variant in the DHX15 gene that was present in both tumor components, suggesting that DHX15 may play an important role in the initiation and development of sarcoma and carcinoma. The patient is followed by regular clinical controls and is alive without signs of disease recurrence 18 months after surgery.
DOI: 10.6084/m9.figshare.24511039
title: Supplementary Material for: Abscopal effect after stereotactic body radiotherapy with nivolumab for lung metastasis of head and neck cancer: a case report

description: The abscopal effect (AE) is a phenomenon, in which radiotherapy exerts an antitumour effect on distant lesions outside the primary irradiated area. Although immune checkpoint inhibitors have been widely studied for their potential to enhance the AE and improve patient outcomes, findings in cases of head and neck cancers remain limited. We report the case of a 72-year-old man who experienced lung oligoprogression during nivolumab treatment for metastatic hypopharyngeal cancer. Stereotactic body radiotherapy (SBRT) was administered to one of the lung lesions, after which both irradiated and non-irradiated lesions regressed. Upon an 18-month follow-up period after SBRT, the patient showed no disease progression or toxicity, and continued receiving nivolumab therapy. The intent behind presenting this case report aimed to contribute to the accumulation of evidence regarding the AE in cases of head and neck cancer.
DOI: 10.6084/m9.figshare.24511039.v1
title: Supplementary Material for: Abscopal effect after stereotactic body radiotherapy with nivolumab for lung metastasis of head and neck cancer: a case report

description: The abscopal effect (AE) is a phenomenon, in which radiotherapy exerts an antitumour effect on distant lesions outside the primary irradiated area. Although immune checkpoint inhibitors have been widely studied for their potential to enhance the AE and improve patient outcomes, findings in cases of head and neck cancers remain limited. We report the case of a 72-year-old man who experienced lung oligoprogression during nivolumab treatment for metastatic hypopharyngeal cancer. Stereotactic body radiotherapy (SBRT) was administered to one of the lung lesions, after which both irradiated and non-irradiated lesions regressed. Upon an 18-month follow-up period after SBRT, the patient showed no disease progression or toxicity, and continued receiving nivolumab therapy. The intent behind presenting this case report aimed to contribute to the accumulation of evidence regarding the AE in cases of head and neck cancer.
DOI: 10.6084/m9.figshare.24504265
title: Supplementary Material for: Mixed diffuse and tumoral form of Bing-Neel Syndrome successfully treated with ibrutinib: A case report

description: Introduction: Bing-Neel Syndrome (BNS) is a rare and heterogenous manifestation of Waldenström Macroglobulinemia (WM) involving central nervous system (CNS) infiltration by malignant lymphoplasmacytic cells. Efforts to standardize diagnostic criteria have improved in recent years, as have treatment options including the use of the Bruton tyrosine kinase inhibitor (BTKI) ibrutinib. Case presentation: Here, we present the case of a 70-year-old male with a remote history of WM previously treated with bendamustine and rituximab, who presented to medical attention with several months of left-sided weakness, headache, and ataxia. Brain magnetic resonance imaging revealed numerous enhancing masses in bilateral cerebral hemispheres, inferior medulla, and upper cervical spine. Laboratory studies showed serum IgM lambda monoclonal gammopathy and elevated free serum kappa and lambda light chains, while cerebrospinal fluid (CSF) flow cytometry revealed CD19+ B-cells. Stereotactic brain biopsy of a right frontal brain lesion was consistent with lymphoplasmacytic lymphoma, confirmed by a positive MYD88 L265P mutation. He received ibrutinib 420 mg orally daily and this resulted in appreciable clinical and radiologic responses, which have persisted over a 31-month period. Conclusion: The advent of molecularly targeted agents and novel therapies for WM has provided patients and clinicians with additional therapeutic options. The use of BTK inhibitors with their high level central nervous system penetrance, in particular, offer a novel way to treat BNS and improve patient overall survival while maintaining a high-level of quality of life. We discuss the importance of MYD88 L265P testing in the context of BNS as well as the expanding role of BTKIs in treating this disease.
DOI: 10.6084/m9.figshare.24504265.v1
title: Supplementary Material for: Mixed diffuse and tumoral form of Bing-Neel Syndrome successfully treated with ibrutinib: A case report

description: Introduction: Bing-Neel Syndrome (BNS) is a rare and heterogenous manifestation of Waldenström Macroglobulinemia (WM) involving central nervous system (CNS) infiltration by malignant lymphoplasmacytic cells. Efforts to standardize diagnostic criteria have improved in recent years, as have treatment options including the use of the Bruton tyrosine kinase inhibitor (BTKI) ibrutinib. Case presentation: Here, we present the case of a 70-year-old male with a remote history of WM previously treated with bendamustine and rituximab, who presented to medical attention with several months of left-sided weakness, headache, and ataxia. Brain magnetic resonance imaging revealed numerous enhancing masses in bilateral cerebral hemispheres, inferior medulla, and upper cervical spine. Laboratory studies showed serum IgM lambda monoclonal gammopathy and elevated free serum kappa and lambda light chains, while cerebrospinal fluid (CSF) flow cytometry revealed CD19+ B-cells. Stereotactic brain biopsy of a right frontal brain lesion was consistent with lymphoplasmacytic lymphoma, confirmed by a positive MYD88 L265P mutation. He received ibrutinib 420 mg orally daily and this resulted in appreciable clinical and radiologic responses, which have persisted over a 31-month period. Conclusion: The advent of molecularly targeted agents and novel therapies for WM has provided patients and clinicians with additional therapeutic options. The use of BTK inhibitors with their high level central nervous system penetrance, in particular, offer a novel way to treat BNS and improve patient overall survival while maintaining a high-level of quality of life. We discuss the importance of MYD88 L265P testing in the context of BNS as well as the expanding role of BTKIs in treating this disease.
DOI: 10.25934/pr00008581
title: Repositioning of neurological drug Aripiprazole for Amyotrophic lateral sclerosis (ALS)  patients

description: Amyotrophic lateral sclerosis (ALS) is a serious disease affecting the nerve cells in the spinal cord that control muscle movement, resulting in a reduction in size and strength of muscles. ALS is designated as an intractable disease by Ministry of Health, Labor and Welfare (MHLW). “The criteria for designated intractable diseases are as follows: (1) rarity (affecting less than 0.1% of the population in Japan), (2) unknown etiology (cause), (3) lack of effective treatment, (4) necessity of long-term treatment, and (5) existence of objective diagnostic criteria (i.e., there are specific measures for recognizing and monitoring the disease)”. Globally, it is reported that there are 400,000 ALS patients and 5600 patients are newly diagnosed each year.

ALS is an incurable disease and patients have limited medical therapies. Currently there are only two medical therapies available, Riluzole and Radicavatm.
Phase III clinical trials indicated that survival, time to death and time to progression was longer for Riluzole compared to placebo. For Radicavatm, quality of life was shown to be better using the ALS Functional Rating scale revised (ALSFRS-R) compared to placebo. 

Aripiprazole is a medication used to treat some mental health conditions. Phase III trials testing whether Aripiprazole could be a potential medication for treating Alzheimer’s disease did not show statistically significant results. 

The primary endpoints in the ALS trials using Radicavatm and the Alzheimer’s trials using Aripiprazole measured similar quality of life endpoints. 
The aim of the research is to analyze the quality of life endpoints in both Radicavatm and Aripiprazole clinical trials and to postulate that the results are similar in Alzheimer and ALS patients. This may further indicate that Aripiprazole has an extended indication to ALS patients although it did not show efficacy in Alzheimer patients.

The purpose of this research is to re-analyze the data using all the patient data without imputation. In addition, analysis of the data using appropriate models such as logistic regression for each of the endpoints is necessary. If the analyses of the two endpoints prompts positive results, repositioning of Aripiprazole as a medical therapy for ALS may be considered.
DOI: 10.6084/m9.figshare.24503704
title: Supplementary Material for: Secondary colo-colic intussusception Caused by Giant Polyp of Sigmoid Colon in a 5-Year-Old Girl

description: Intussusception is common in infants and young children. The most common type is small intestinal intussusception or ileo-colic intussusception. Colonic intussusception is rare. Intestinal polyps, especially large polyps or multiple polyps, can cause intussusception. Here We report a rare case of colo-colic intussusception caused by a giant juvenile polyp of sigmoid colon and the patient achieved good clinical effect through polypectomy under colonoscopy. So When children have colonic intussusception, the possibility of colonic polyps should be considered.
DOI: 10.6084/m9.figshare.24503704.v1
title: Supplementary Material for: Secondary colo-colic intussusception Caused by Giant Polyp of Sigmoid Colon in a 5-Year-Old Girl

description: Intussusception is common in infants and young children. The most common type is small intestinal intussusception or ileo-colic intussusception. Colonic intussusception is rare. Intestinal polyps, especially large polyps or multiple polyps, can cause intussusception. Here We report a rare case of colo-colic intussusception caused by a giant juvenile polyp of sigmoid colon and the patient achieved good clinical effect through polypectomy under colonoscopy. So When children have colonic intussusception, the possibility of colonic polyps should be considered.
DOI: 10.6084/m9.figshare.24504151
title: Supplementary Material for: Successful Endoscopic Removal of Anisakis Larvae that Deeply Invaded the Gastric Mucosa Using Jumbo Forceps

description: Anisakiasis is a parasitic disease caused by the ingestion of raw or uncooked seafood infected with third-stage larvae of anisakid nematodes. Generally, the larvae parasites live at the surface of the mucosa, but in this case, the larvae deeply invaded its head into the gastric mucosa and were not removable with a conventional biopsy forceps. In our case, we demonstrated the usefulness of jumbo forceps to remove the Anisakis larvae in such a situation.
DOI: 10.6084/m9.figshare.24297058.v1
title: Supplementary Material for: Outcomes and Feasibility of an Occupational Care Programme (TERRA) to Support Work Ability of Rare and Advanced Cancer Patients: A Report of 7 Cases

description: Introduction: Advancements in the field of oncology are allowing patients to live longer, with enhanced quality of life (QoL). Accordingly, more patients with cancer are expressing the desire to return to work (RTW). Previous research has indicated that patients with a rare or advanced cancer can experience unique problems in the RTW process. Methods: This pilot study evaluated the outcomes and feasibility of the occupational care programme TERRA (i.e., recalibraTe lifE and woRk with and afteR cAncer) for patients with a rare or advanced cancer. Four rare cancer patients and three advanced cancer patients completed TERRA; a supportive occupational care programme consisting of five online group sessions over a two-month period. Pre- and post-intervention outcomes were collected using validated self-report questionnaires. The primary outcome was work ability. Secondary outcomes included QoL, anxiety and depression, fatigue, unmet needs, self-efficacy, readiness for RTW, work intention, work involvement, and work-life conflict. Feasibility was assessed using the RE-AIM model. Results: Changes in work ability scores were inconsistent across participants. Well-being outcomes generally improved following the intervention. Feasibility was evaluated positively by both participants and trainers. Discussion/Conclusion: A multidisciplinary approach may further improve outcomes of occupational interventions supporting rare and advanced cancer patients. An effectiveness study to evaluate the outcomes and feasibility of the programme is deemed necessary.
DOI: 10.6084/m9.figshare.24486310
title: Supplementary Material for: Bone mineral parameters in peritoneal dialysis patients after lowering calcium concentration in dialysis fluids – a case series in patients using Icodextrin

description: In patients treated with peritoneal dialysis (PD), lowering the calcium level in PD fluids results in lower serum calcium levels and higher parathyroid hormone (PTH) levels. It is hypothesized that this effect is attenuated when patients are using icodextrin 7.5% for the once daily long dwell (containing high calcium concentration). In this case series we included 8 stable PD patients (mean age 68 ± 13 years, 7 male), all using icodextrin 7.5% (containing 1.75mmol/l calcium) for the once-dialy long dwell. The calcium content of the PD fluids for the remaining dwells was lowered from 1.75 mmol/l calcium to 1.25 mmol/l. Bone mineral parameters and phosphate prescription at baseline, 6 weeks after this change and after 6 months were compared. After lowering calcium concentration of the PD fluids - except for the icodextrin 7.5% - from 1.75 mmol/l to 1.25 mmol/l, calcium levels changed from 2.32 ± 0.11 to 2.29 ± 0.12 (p=NS); intact PTH from 39,6 ± 28,3 to 64.9 ± 34.5pmol/L (p=0.045) and AF from 104.13 ± 48.75 to 101.38 ± 32.39 (p=NS). After six months all bone mineral parameters were similar to baseline levels, however slightly higher calcium-based phosphate binders were prescribed. Lowering calcium content from 1.75 mmol/l to 1.25 mmol/l in PD fluid in patients on icodextrin resulted in stable calcium values, a temporal increase in iPTH and a modest increase in calcium-based phosphate binder prescription. Using icodextrin for the long once-daily dwell appears to attenuate the effects on bone mineral parameters when lowering the calcium concentration of the short dwells.
DOI: 10.6084/m9.figshare.24486310.v1
title: Supplementary Material for: Bone mineral parameters in peritoneal dialysis patients after lowering calcium concentration in dialysis fluids – a case series in patients using Icodextrin

description: In patients treated with peritoneal dialysis (PD), lowering the calcium level in PD fluids results in lower serum calcium levels and higher parathyroid hormone (PTH) levels. It is hypothesized that this effect is attenuated when patients are using icodextrin 7.5% for the once daily long dwell (containing high calcium concentration). In this case series we included 8 stable PD patients (mean age 68 ± 13 years, 7 male), all using icodextrin 7.5% (containing 1.75mmol/l calcium) for the once-dialy long dwell. The calcium content of the PD fluids for the remaining dwells was lowered from 1.75 mmol/l calcium to 1.25 mmol/l. Bone mineral parameters and phosphate prescription at baseline, 6 weeks after this change and after 6 months were compared. After lowering calcium concentration of the PD fluids - except for the icodextrin 7.5% - from 1.75 mmol/l to 1.25 mmol/l, calcium levels changed from 2.32 ± 0.11 to 2.29 ± 0.12 (p=NS); intact PTH from 39,6 ± 28,3 to 64.9 ± 34.5pmol/L (p=0.045) and AF from 104.13 ± 48.75 to 101.38 ± 32.39 (p=NS). After six months all bone mineral parameters were similar to baseline levels, however slightly higher calcium-based phosphate binders were prescribed. Lowering calcium content from 1.75 mmol/l to 1.25 mmol/l in PD fluid in patients on icodextrin resulted in stable calcium values, a temporal increase in iPTH and a modest increase in calcium-based phosphate binder prescription. Using icodextrin for the long once-daily dwell appears to attenuate the effects on bone mineral parameters when lowering the calcium concentration of the short dwells.
DOI: 10.5517/ccdc.csd.cc2c5g89
title: CCDC 2179990: Experimental Crystal Structure Determination

description: Related Article: Chandra S Azad|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2cb7kj
title: CCDC 2184587: Experimental Crystal Structure Determination

description: Related Article: Nagappan Sivakumar, Manickam Bakthadoss, Gayathri Dasararaju, Devadasan Velmurugan|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2cb7lk
title: CCDC 2184588: Experimental Crystal Structure Determination

description: Related Article: Nagappan Sivakumar, Manickam Bakthadoss, Geetha Madhavan, Gayathri Dasararaju, Devadasan Velmurugan|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2cb7ml
title: CCDC 2184589: Experimental Crystal Structure Determination

description: Related Article: Nagappan Sivakumar, Manickam Bakthadoss, Geetha Madhavan, Gayathri Dasararaju, Devadasan Velmurugan|2023|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.6084/m9.figshare.24486301
title: Supplementary Material for: Effects of a web-based behavioral activation intervention on depressive symptoms, activation, motivation, and volition: results of a randomized-controlled trial

description: Introduction: Behavioral activation (BA) is effective for the treatment of depression. The Health Action Process Approach (HAPA), which is derived from health psychology, can provide a motivational-volitional framework of behavioral activation. Objective: This study investigates the efficacy of a HAPA-based internet-delivered BA intervention (iBA; called InterAKTIV) in individuals with depression, also assessing HAPA-based motivational and volitional outcomes. Methods: In a two-arm randomized controlled efficacy trial with a parallel design, 128 participants with a major depressive episode were randomly allocated to the intervention group (IG; TAU + immediate access to iBA) or control group (CG; TAU + access to iBA after follow-up). The primary outcome of clinician-rated depressive symptoms and secondary outcomes were assessed at baseline (T1), 8 weeks (T2), 6-month after randomization (T3). Data were analyzed on an intention-to-treat basis. Results: Linear mixed model analyses revealed a significant group*time interaction effect on clinician-rated depressive symptoms favoring the IG (F2, 156.0 = 7.40; p &lt; 0.001, d = 0.79 at T2, d = 0.25 at T3). The IG was also superior regarding self-rated depressive symptoms, behavioral activation, most motivational, and all volitional outcomes. Conclusion: This study shows that HAPA-based iBA can significantly improve clinician-rated depressive symptoms, as well as outcomes used in the HAPA model in people with depression. Building on these efficacy results, in the next step, the relationship between BA interventions and activity levels should be investigated, taking into account motivation and volition as potential mediators.
DOI: 10.6084/m9.figshare.24486301.v1
title: Supplementary Material for: Effects of a web-based behavioral activation intervention on depressive symptoms, activation, motivation, and volition: results of a randomized-controlled trial

description: Introduction: Behavioral activation (BA) is effective for the treatment of depression. The Health Action Process Approach (HAPA), which is derived from health psychology, can provide a motivational-volitional framework of behavioral activation. Objective: This study investigates the efficacy of a HAPA-based internet-delivered BA intervention (iBA; called InterAKTIV) in individuals with depression, also assessing HAPA-based motivational and volitional outcomes. Methods: In a two-arm randomized controlled efficacy trial with a parallel design, 128 participants with a major depressive episode were randomly allocated to the intervention group (IG; TAU + immediate access to iBA) or control group (CG; TAU + access to iBA after follow-up). The primary outcome of clinician-rated depressive symptoms and secondary outcomes were assessed at baseline (T1), 8 weeks (T2), 6-month after randomization (T3). Data were analyzed on an intention-to-treat basis. Results: Linear mixed model analyses revealed a significant group*time interaction effect on clinician-rated depressive symptoms favoring the IG (F2, 156.0 = 7.40; p &lt; 0.001, d = 0.79 at T2, d = 0.25 at T3). The IG was also superior regarding self-rated depressive symptoms, behavioral activation, most motivational, and all volitional outcomes. Conclusion: This study shows that HAPA-based iBA can significantly improve clinician-rated depressive symptoms, as well as outcomes used in the HAPA model in people with depression. Building on these efficacy results, in the next step, the relationship between BA interventions and activity levels should be investigated, taking into account motivation and volition as potential mediators.